Eosinophilia: secondary, clonal and idiopathic

Br J Haematol. 2006 Jun;133(5):468-92. doi: 10.1111/j.1365-2141.2006.06038.x.

Abstract

Blood eosinophilia signifies either a cytokine-mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological neoplasm (primary). Secondary eosinophilia is usually associated with parasitosis in Third World countries and allergic conditions in the West. Primary eosinophilia is operationally classified as being clonal or idiopathic, depending on the respective presence or absence of a molecular, cytogenetic or histological evidence for a myeloid malignancy. The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment.

Publication types

  • Review

MeSH terms

  • Benzamides
  • Bone Marrow / pathology
  • Chromosome Aberrations
  • Cytokines / immunology
  • Eosinophilia / drug therapy
  • Eosinophilia / etiology*
  • Eosinophilia / genetics
  • Gene Rearrangement / genetics
  • Humans
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / etiology
  • Hypereosinophilic Syndrome / genetics
  • Imatinib Mesylate
  • Parasitic Diseases / complications
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Pulmonary Eosinophilia / drug therapy
  • Pulmonary Eosinophilia / etiology
  • Pulmonary Eosinophilia / genetics
  • Pyrimidines / therapeutic use
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Receptor, Platelet-Derived Growth Factor beta / genetics

Substances

  • Benzamides
  • Cytokines
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Receptor, Fibroblast Growth Factor, Type 1
  • Receptor, Platelet-Derived Growth Factor alpha
  • Receptor, Platelet-Derived Growth Factor beta